Hui Yang
huiyang@ion.ac.cn
Chinese, English
Shanghai
University of Chinese Academy of Sciences
Medical School
  • 2009-09--2012-07 PhD: Shanghai Institute for Biological Sciences, Chinese Academy of Sciences
  • 2007-09--2009-07 Master's: Shanghai Institute for Biological Sciences, Chinese Academy of Sciences
  • 2003-09--2007-07 Bachelor's: Shanghai Jiao Tong University
  • 2014-05~Present - Shanghai Institute for Biological Sciences, Chinese Academy of Sciences - Researcher
  • 2012-12~2014-04 - Whitehead Institute, MIT - Postdoctoral Researcher
  • 2012-08~2012-12 - Shanghai Institute for Biological Sciences, Chinese Academy of Sciences - Assistant Researcher
  • Outstanding Youth Science and Technology Innovation Talent Award, Chinese Academy of Sciences, 2018
  • Shanghai Youth Top Talent, 2015
  • Excellent Youth Science Fund, National Level, 2015
  • Shanghai Graduate Excellent Achievement (Thesis), 2014
  • Youth ****, National Level, 2014
  • Chinese Academy of Sciences Excellent Doctoral Dissertation Award, 2013
  • Wu Rui Scholarship, National Level, 2012
  • Chinese Academy of Sciences President's Award, Special Prize, 2012
  • Lilly Scholarship, First Prize, 2012
Gene Editing
CRISPR/Cas9
Disease Animal Models
  • Programmable A-to-Y base editing by fusing an adenine base editor with an N-methylpurine DNA glycosylase, Tong, Huawei, Wang, Xuchen, Liu, Yuanhua, Liu, Nana, Li, Yun, Luo, Jiamin, Ma, Qian, Wu, Danni, Li, Jiyong, Xu, Chunlong, Yang, Hui, 2023
  • Mini-dCas13X-mediated RNA editing restores dystrophin expression in a humanized mouse model of Duchenne muscular dystrophy, Li, Guoling, Jin, Ming, Li, Zhifang, Xiao, Qingquan, Lin, Jiajia, Yang, Dong, Liu, Yuanhua, Wang, Xing, Xie, Long, Ying, Wenqin, Wang, Haoqiang, Zuo, Erwei, Shi, Linyu, Wang, Ning, Chen, Wanjin, Xu, Chunlong, Yang, Hui, 2023
  • A high-fidelity RNA-targeting Cas13 restores paternal Ube3a expression and improves motor functions in Angelman syndrome mice, Jinhui Li, Zhixin Shen, Yajing Liu, Zixiang Yan, Yuanhua Liu, Xiang Lin, Junjie Tang, Ruimin Lv, Guannan Geng, ZhiQi Xiong, Changyang Zhou, Hui Yang, 2023
  • Develop a Compact RNA Base Editor by Fusing ADAR with Engineered EcCas6e, Wang, Xing, Zhang, Renxia, Yang, Dong, Li, Guoling, Fan, Zhanqing, Du, Hongting, Wang, Zikang, Liu, Yuanhua, Lin, Jiajia, Wu, Xiaoqing, Shi, Linyu, Yang, Hui, Zhou, Yingsi, 2023
  • In vivo treatment of tyrosinaemia with hypercompact Cas12f1, Guo, Ruochen, Li, Zhifang, Li, Guoling, Zhang, Hainan, Zhang, Chang, Huo, Xiaona, Zhang, Xiaoyin, Yang, Xiali, Yang, Rongrong, Liu, Yuanhua, Sun, Xiaozhi, Liu, Xinyu, Yang, Hui, Zhou, Yingsi, Xu, Chunlong, 2023
  • Treatment of autosomal dominant retinitis pigmentosa caused by RHO-P23H mutation with high-fidelity Cas13X in mice, Zixiang Yan, Yuqin Yao, Luyao Li, Lingqiong Cai, Haiwei Zhang, Shenghai Zhang, Qingquan Xiao, Xing Wang, Erwei Zuo, Chunlong Xu, Jihong Wu, Hui Yang, 2023
  • RNA base editing therapy cures hearing loss induced by OTOF gene mutation, Yuanyuan Xue, Yong Tao, Xing Wang, Xueling Wang, Yilai Shu, Yuanhua Liu, Wen Kang, Sifan Chen, Zhenzhe Cheng, Boou Yan, Yanwei Xie, Lanting Bi, Haitao Jia, Jinhui Li, Qingquan Xiao, Liying Chen, Xuan Yao, Linyu Shi, Hui Yang, Hao Wu, 2023
  • Human 8-cell embryos enable efficient induction of disease-preventive mutations without off-target effect by cytosine base editor, Wei, Yinghui, Zhang, Meiling, Hu, Jing, Zhou, Yingsi, Xue, Mingxing, Yin, Jianhang, Liu, Yuanhua, Feng, Hu, Zhou, Ling, Li, Zhifang, Wang, Dongshuang, Zhang, Zhiguo, Zhou, Yin, Liu, Hongbin, Yao, Ning, Zuo, Erwei, Hu, Jiazhi, Du, Yanzhi, Li, Wen, Xu, Chunlong, Yang, Hui, 2023
  • Engineered CRISPR-OsCas12f1 and RhCas12f1 with robust activities and expanded target range for genome editing, Xiangfeng Kong, Hainan Zhang, Guoling Li, Zikang Wang, Xuqiang Kong, Lecong Wang, Mingxing Xue, Weihong Zhang, Yao Wang, Jiajia Lin, Jingxing Zhou, Xiaowen Shen, Yinghui Wei, Na Zhong, Weiya Bai, Yuan Yuan, Linyu Shi, Yingsi Zhou, Hui Yang, 2023
  • Development of miniature base editors using engineered IscB nickase, Han, Dingyi, Xiao, Qingquan, Wang, Yifan, Zhang, Hainan, Dong, Xue, Li, Guoling, Kong, Xiangfeng, Wang, Shihao, Song, Jinhui, Zhang, Weihong, Zhou, Jingxing, Bi, Lanting, Yuan, Yuan, Shi, Linyu, Zhong, Na, Yang, Hui, Zhou, Yingsi, 2023
  • Programmable deaminase-free base editors for G-to-Y conversion by engineered glycosylase, Tong, Huawei, Liu, Nana, Wei, Yinghui, Zhou, Yingsi, Li, Yun, Wu, Danni, Jin, Ming, Cui, Shuna, Li, Hengbin, Li, Guoling, Zhou, Jingxing, Yuan, Yuan, Zhang, Hainan, Shi, Linyu, Yao, Xuan, Yang, Hui, 2023
  • Ptbp1 knockdown failed to induce astrocytes to neurons in vivo, Yang, Guixiang, Yan, Zixiang, Wu, Xiaoqing, Zhang, Meng, Xu, Chunlong, Shi, Linyu, Yang, Hui, Fang, Kailun, 2023
  • An engineered xCas12i with high activity, high specificity, and broad PAM range, Zhang, Hainan, Kong, Xiangfeng, Xue, Mingxing, Hu, Jing, Wang, Zikang, Wei, Yinghui, Wang, Haoqiang, Zhou, Jingxing, Zhang, Weihong, Xu, Mengqiu, Shen, Xiaowen, Yin, Fengcai, Ai, Zhiyuan, Huang, Guangyan, Xia, Junhui, Song, Xueqiong, Li, Hengbin, Yuan, Yuan, Li, Jinhui, Zhong, Na, Zhang, Meiling, Zhou, Yingsi, Yang, Hui, 2023
  • Develop an efficient and specific AAV-based labeling system for Muller glia in mice, Gao, Yanxia, Fang, Kailun, Yan, Zixiang, Zhang, Haiwei, Geng, Guannan, Wu, Weiwei, Xu, Ding, Zhang, Heng, Zhong, Na, Wang, Qifang, Cai, Minqing, Zuo, Erwei, Yang, Hui, 2022
  • Treatment of autosomal recessive hearing loss via in vivo CRISPR/Cas9-mediated optimized homology-directed repair in mice, Gu, Xi, Hu, Xinde, Wang, Daqi, Xu, Zhijiao, Wang, Fang, Li, Di, Li, Genglin, Yang, Hui, Li, Huawei, Zuo, Erwei, Shu, Yilai, 2022
  • Human cleaving embryos enable efficient mitochondrial base-editing with DdCBE, Wei, Yinghui, Xu, Chunlong, Feng, Hu, Xu, Kui, Li, Zhifang, Hu, Jing, Zhou, Ling, Wei, Yu, Zuo, Zhenrui, Zuo, Erwei, Li, Wen, Yang, Hui, Zhang, Meiling, 2022
  • High-fidelity Cas13 variants for targeted RNA degradation with minimal collateral effects, Tong, Huawei, Huang, Jia, Xiao, Qingquan, He, Bingbing, Dong, Xue, Liu, Yuanhua, Yang, Xiali, Han, Dingyi, Wang, Zikang, Ying, Wenqin, Zhang, Runze, Wei, Yu, Wang, Xuchen, Xu, Chunlong, Zhou, Yingsi, Li, Yanfei, Cai, Minqing, Wang, Qifang, Xue, Mingxing, Li, Guoling, Fang, Kailun, Zhang, Hainan, Yang, Hui, 2022
  • Rescue of autosomal dominant hearing loss by in vivo delivery of mini dCas13X-derived RNA base editor, Xiao, Qingquan, Xu, Zhijiao, Xue, Yuanyuan, Xu, Chunlong, Han, Lei, Liu, Yuanhua, Wang, Fang, Zhang, Runze, Han, Shuang, Wang, Xing, Li, GengLin, Li, Huawei, Yang, Hui, Shu, Yilai, 2022
  • Mitochondrial base editor DdCBE causes substantial DNA off-target editing in nuclear genome of embryos, Wei, Yinghui, Li, Zhifang, Xu, Kui, Feng, Hu, Xie, Long, Li, Di, Zuo, Zhenrui, Zhang, Meiling, Xu, Chunlong, Yang, Hui, Zuo, Erwei, 2022
  • Safeguarding genome integrity during gene-editing therapy in a mouse model of age-related macular degeneration, Yin, Jianhang, Fang, Kailun, Gao, Yanxia, Ou, Liqiong, Yuan, Shaopeng, Xin, Changchang, Wu, Weiwei, Wu, Weiwei, Hong, Jiaxu, Yang, Hui, Hu, Jiazhi, 2022
  • Gene editing in a Myo6 semi-dominant mouse model rescues auditory function, Xue, Yuanyuan, Hu, Xinde, Wang, Daqi, Li, Di, Li, Yige, Wang, Fang, Huang, Mingqian, Gu, Xi, Xu, Zhijiao, Zhou, Jinan, Wang, Jinghan, Chai, Renjie, Shen, Jun, Chen, ZhengYi, Li, GengLin, Yang, Hui, Li, Huawei, Zuo, Erwei, Shu, Yilai, 2022
  • Programmable RNA editing with compact CRISPR-Cas13 systems from uncultivated microbes, Xu, Chunlong, Zhou, Y
Gene Editing Crispr Cas9 Genomics Biotechnology Genetic Engineering Molecular Biology Genome Editing Biomedical Research Therapeutics

Contact us

Let's talk!
* Required
* Required
* Required
* Invalid email address
By submitting this form, you agree that IoT ONE may contact you with insights and marketing messaging.
No thanks, I don't want to receive any marketing emails from IoT ONE.
Submit

Thank you for your message!
We will contact you soon.